We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Osmotica Pharmaceuticals PLC | NASDAQ:OSMT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.11 | 1.09 | 1.15 | 0 | 01:00:00 |
| | |
Per Share
and Accompanying Warrant |
| |
Total
|
| ||||||
Public offering price(1)
|
| | | $ | | | | | $ | | | ||
Underwriting discounts and commissions(2)
|
| | | $ | | | | | $ | | | ||
Proceeds to us, before expenses
|
| | | $ | | | | | $ | | | |
| | |
Page
|
| |||
PROSPECTUS SUPPLEMENT
|
| ||||||
| | | | S-ii | | | |
| | | | S-1 | | | |
| | | | S-4 | | | |
| | | | S-6 | | | |
| | | | S-10 | | | |
| | | | S-12 | | | |
| | | | S-13 | | | |
| | | | S-14 | | | |
| | | | S-16 | | | |
| | | | S-26 | | | |
| | | | S-31 | | | |
| | | | S-31 | | | |
| | | | S-31 | | | |
| | | | S-31 | | |
| | | | | ii | | | |
| | | | | iii | | | |
| | | | | iv | | | |
| | | | | iv | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | 32 | | | |
| | | | | 33 | | | |
| | | | | 38 | | | |
| | | | | 39 | | | |
| | | | | 39 | | | |
| | | | | 40 | | |
|
Assumed public offering price per ordinary share and accompanying warrant in this offering
|
| | | $ | 3.06 | | | | | $ | | | |
|
Pro forma net tangible book value per ordinary share as of June 30, 2021
|
| | | $ | (0.18) | | | | | | | | |
|
Increase per ordinary share as of June 30, 2021 attributable to new investors
|
| | | $ | 0.32 | | | | | | | | |
|
As-adjusted pro forma net tangible book value per ordinary share after this offering
|
| | | | | | | | | $ | 0.14 | | |
|
Dilution per ordinary share to investors participating in this offering
|
| | | | | | | | | $ | 2.92 | | |
| Albania | | | Finland | | | Malaysia | | | Slovenia | |
| Armenia | | | France | | | Malta | | | South Africa | |
| Australia | | | Georgia | | | Mexico | | | Spain | |
| Austria | | | Germany | | | Moldova | | | Sweden | |
| Bahrain | | | Ghana | | | Montenegro | | | Switzerland | |
| Belarus | | | Greece | | | Morocco | | | Thailand | |
| Belgium | | | Hong Kong | | | Netherlands | | |
The Republic Of Turkey
|
|
| Bosnia & Herzegovina | | | Hungary | | | New Zealand | | | Ukraine | |
| Botswana | | | Iceland | | | Norway | | | United Arab Emirates | |
| Bulgaria | | | India | | | Pakistan | | | United Kingdom | |
| Canada | | | Israel | | | Panama | | | United States | |
| Chile | | | Italy | | | Poland | | | Uzbekistan | |
| China | | | Japan | | | Portugal | | | Vietnam | |
| Croatia | | | Kazakhstan | | | Qatar | | | Zambia | |
| Cyprus | | | Korea | | | Romania | | | | |
| Czech Republic | | | Kuwait | | | Russia | | | | |
| Denmark | | | Latvia | | | Saudi Arabia | | | | |
| Egypt | | | Lithuania | | | Serbia | | | | |
| Estonia | | | Luxembourg | | | Singapore | | | | |
| Ethiopia | | | Macedonia | | | Slovak Republic | | | | |
| | |
Per Share and
Accompanying Warrant |
| |
Total
Without Option |
| |
Total With
Option |
| |||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | | $ | | | | |
Underwriting discounts and commissions
|
| | | $ | | | | | $ | | | | | | $ | | | | |
Proceeds, before expenses and fees, to us
|
| | | $ | | | | | $ | | | | | | $ | | | |
| | | | | ii | | | |
| | | | | iii | | | |
| | | | | iv | | | |
| | | | | iv | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | 32 | | | |
| | | | | 33 | | | |
| | | | | 38 | | | |
| | | | | 39 | | | |
| | | | | 39 | | | |
| | | | | 40 | | |
Name and Address
|
| |
Number of
Shares Beneficially Owned Prior to Offering |
| |
Number of
Shares Registered for Sale |
| |
Number of
Shares to be Owned after the Offering(1) |
| |
Percent of
Outstanding Shares to be Owned after the Offering(1) |
| ||||||||||||
Investment funds affiliated with Avista Capital Partners(2)
|
| | | | 21,700,785 | | | | | | 21,700,785 | | | | | | — | | | | | | — | | |
Altchem(3) | | | | | 23,667,540 | | | | | | 23,667,540 | | | | | | — | | | | | | — | | |
1 Year Osmotica Pharmaceuticals Chart |
1 Month Osmotica Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions